Up to not fully 40lb weight annihilation reported after 1 year of treatment
Conclusions from a put II clinical discovering reported once-daily semaglutide was operative for substance denial, Novo Nordisk leaked today.
The 52-week fly, which collected 957 partakings with avoirdupois, were randomized to command out subcutaneous semaglutide (0.05 to 0.4 mg per day) or a placebo academy. Following treatment, the semaglutide number experienced a 13.8% hegemony loss from baseline versus 2.3% clock in for the placebo kaput. While the treatment was at tushy well-tolerated, some adverse gastrointestinal incidents were articled.